RevenanasBook a free audit

M&A

3 Biotech Takeover Targets After Apogee Deal

June 23, 2026

Biotech

M&A

Key Facts

Signal Type

M&A

Industry

Biotech

Companies

AbbVie, Syndax, Nektar Therapeutics, Viking Therapeutics, Apogee Therapeutics

Date

June 23, 2026

What Happened

AbbVie announced the acquisition of Apogee Therapeutics, a late-stage immunology biotech, signaling renewed big pharma interest in clinical-stage assets. This deal has put Syndax Pharmaceuticals, Viking Therapeutics, and Nektar Therapeutics on Wall Street's M&A watchlists.

Who Is Affected

Syndax Pharmaceuticals (SNDX) is the most likely target due to its two FDA-approved drugs, revenue growth, and existing partnership with Incyte. Viking Therapeutics (VKTX) and Nektar Therapeutics (NKTR) are also in focus but face higher market caps or longer timelines.

Market Impact

  • Syndax: $1.71B market cap, 224% revenue growth, Incyte as logical acquirer
  • Viking: $3.76B market cap, GLP-1/GIP obesity drug in Phase 3
  • Nektar: $2.22B market cap, immunology asset heading to Phase 3

What to Watch

Monitor Syndax's Q2 earnings and Incyte's partnership moves, as these could trigger a bid. Viking's Phase 3 data and Nektar's funding runway are secondary catalysts.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner